Phone (303) 825-TUCC (8822)      Toll-Free (877) 825-8898
 

Urology News

Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.

* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.

  • February 16, 2017
    Factors predicting urologic cancer in females with microhematuria

    Older age, history of smoking, and gross hematuria predict urologic cancer in women with microscopic hematuria, according to a study published in the February issue of the American Journal of Obstetrics & Gynecology

  • February 2, 2017
    Hormone blockers can prolong life if prostate cancer returns

    Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.

    The finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.

  • January 24, 2017
    Metastatic prostate cancer to the gastrointestinal tract

     Prostate cancer is the second most common cancer among men in the United States, with close to 200,000 new cases estimated in 2016; close to 26,000 deaths will be attributed to the disease.1 Approximately 1 out of every 7 men in the US will be diagnosed with prostate cancer in his life, though diagnoses become more common with advanced age.

     
    Prostate cancer frequently metastasizes to the bones, lymph nodes, lungs, liver, and brain. Rarely, however, patients will develop metastases to the gastrointestinal tract (GIT), which limit treatment options. In a large post-mortem study, 2.5% of patients had evidence of prostate cancer to the stomach on autopsy.
  • January 11, 2017
    New prostate cancer grading system validated

    A proposed simplere grading system for prostate cancer (PCa) can predict the risk of dying from PCa, according to a new study. 

    In the new system, PCa patients are placed into 1 of 5 grade groups based on primary and secondary Gleason score (GS) and other criteria, with Grade Group 1 indicating the most favorable prognosis and Grade Group 5 the least favorable. GS 6 cancers (3 + 3) are placed into Grade Group 1 and GS 7 cancers are subdivided into 3 + 4 and 4 + 3 disease. GS 3 + 4 cancers are associated with significantly better prognoses than GS 4 + 3 cancers and are placed into Grade Group 2 and 3, respectively. The new system also subdivides GS 8–10 cancers into GS 8 and GS 9–10 cancers.

  • December 6, 2016
    Cancer patients benefit from exercise during, after treatment

    Exercising during and after cancer treatment is safe and improves quality of life, fitness, and physical functioning, according to research presented at the American Institute for Cancer Research's Research Conference in Washington, DC.

  • November 9, 2016
    New oncgene may contribute to high incidence of prostate cancer among African American men

    A team of scientists has identified MNX1 as a new oncogene - a gene than can cause cancer - that is more active in African American prostate cancer than in European American prostate cancer. The finding suggests that genetic factors can contribute, at last in part, to the higher incidence of prostate cancer among African American men compared with men of other ethnic groups. The team includes scientists at Baylor College of Medicine, Third Military Medical University in China, the Michael E. DeBakey VA Medical Center, and Agilent Technologies India Pvt. Ltd. The study appeared Aug. 31 in Cancer Research.

     

    "African Americans have about one-and-a-half times the incidence and twice the mortality associated with prostate cancer of European Americans, and the reasons for this are not clear," said senior author Dr. Michael Ittmann, professor of pathology & immunology at Baylor and the Michael E. DeBakey Department of VA Medical Center.

  • October 27, 2016
    It's time for a new dialogue about prostate cancer screening

    In recent days Ben Stiller made headlines for his courageous and honest account of his prostate cancer diagnosis. He speaks candidly about how fortunate he was to have a doctor that did a baseline PSA test, even though it is not recommended by the US Preventive Services Task Force (USPSTF) guidelines.  A PSA test is a non-invasive, safe blood test that measures amount of prostate-specific antigen (PSA) in a man’s blood and when monitored over time can be an early indicator of prostate cancer. 

     

    Mr. Stiller’s story highlights an issue that for too long has been overlooked.  Getting this life-saving test should not come down to which doctor you choose.  It should be standard.

  • October 8, 2016
    Prostate cancer study details value of treatments

    A new study offers important information to men who are facing difficult decisions about how to treat prostate cancer in its early stages, or whether to treat it at all.

    Researchers followed patients for 10 years and found no difference in death rates between men who were picked at random to have surgery or radiation, or to rely on “active monitoring” of the cancer, with treatment only if it progressed.

  • August 29, 2016
    Radical local treatment and thorough examination can halve mortality from prostate cancer

    Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion. This is according to a new study conducted by researchers at Umeå University in Sweden and published in European Urology.

  • June 28, 2016
    PSA of 0.4 ng/ml predicts prostate cancer progression

    A prostate-specific antigen cut point of ≥0.4 ng/mL predicts future disease progression, according to a study published in The Journal of Urology.

     
    Amir Toussi, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues reviewed long-term prostatectomy outcomes to examine the most appropriate prostate-specific antigen cut point that predicts subsequent disease progression. Data were included for 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy.

Request an Appointment

TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.

read more »